Perspective Therapeutics Inc (CATX)

$3.77 -0.11 (-2.84%)
Market Cap 442.39M
Revenue (ttm) 880,000.00
Net Income (ttm) -103.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -11,718.18%
Debt to Equity Ratio 0.01
Volume 1,329,700
Avg Vol 1,486,150
Day's Range N/A - N/A
Shares Out 114.02M
Stochastic %K 37%
Beta 1.75
Analysts Strong Sell
Price Target $12.86

Company Profile

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a b...

Industry: Medical Devices
Sector: Healthcare
Phone: 206 676 0900
Address:
2401 Elliott Avenue, Suite 320, Seattle, United States
Xanderzzzzzzz
Xanderzzzzzzz May. 13 at 3:33 PM
$CATX
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz May. 13 at 2:16 PM
$CATX
0 · Reply
jto2
jto2 May. 13 at 12:48 AM
FDA predictability is back on the menu. Bullish for $CATX.
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz May. 12 at 10:28 PM
$CADL $IOVA $CATX
5 · Reply
rughead64
rughead64 May. 12 at 5:04 PM
$CATX Morgan stanley 3 million shares
2 · Reply
watchaddict
watchaddict May. 12 at 5:03 PM
$CATX 500
0 · Reply
watchaddict
watchaddict May. 12 at 1:25 PM
$CATX 100
1 · Reply
PismoSpike
PismoSpike May. 12 at 12:06 PM
$CATX Hi folks, still seeing old timers, that's nice. How are we feeling about the stock? How's the business plan and business doing now in you and since merger? Any opinions about building a position again?
3 · Reply
rughead64
rughead64 May. 12 at 10:21 AM
$CATX short interest dropped a little, but is still 13 million.
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz May. 11 at 9:11 PM
$CATX
0 · Reply
Latest News on CATX
Perspective Therapeutics price target lowered to $6 from $7 at BofA

2026-05-12T16:04:03.000Z - 23 hours ago

Perspective Therapeutics price target lowered to $6 from $7 at BofA

Perspective Therapeutics reports Q1 EPS (25c), consensus (30c)

2026-05-11T23:16:42.000Z - 1 day ago

Perspective Therapeutics reports Q1 EPS (25c), consensus (30c)

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results

May 11, 2026, 4:07 PM EDT - 1 day ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results

Perspective Therapeutics to Provide Several Upcoming Corporate Updates

Apr 24, 2026, 6:30 AM EDT - 19 days ago

Perspective Therapeutics to Provide Several Upcoming Corporate Updates

Perspective reports results from Phase 1/2a clinical trial of (212Pb)VMT-alpha-NET

2026-04-20T10:10:51.000Z - 23 days ago

Perspective reports results from Phase 1/2a clinical trial of (212Pb)VMT-alpha-NET

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting

Apr 20, 2026, 6:00 AM EDT - 23 days ago

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting

Perspective Therapeutics to Participate in Upcoming Investor Conferences

Apr 2, 2026, 7:00 AM EDT - 5 weeks ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences

Perspective Therapeutics price target raised to $13 from $12 at H.C. Wainwright

2026-03-23T10:10:08.000Z - 7 weeks ago

Perspective Therapeutics price target raised to $13 from $12 at H.C. Wainwright

Perspective Therapeutics price target raised to $8 from $7 at UBS

2026-03-19T12:28:39.000Z - 7 weeks ago

Perspective Therapeutics price target raised to $8 from $7 at UBS

Perspective Therapeutics price target raised to $13 from $11 at B. Riley

2026-03-18T12:51:16.000Z - 2 months ago

Perspective Therapeutics price target raised to $13 from $11 at B. Riley

Perspective Therapeutics price target raised to $8 from $7 at UBS

2026-03-18T12:07:41.000Z - 2 months ago

Perspective Therapeutics price target raised to $8 from $7 at UBS

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026

Mar 17, 2026, 4:45 PM EDT - 2 months ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results

Mar 16, 2026, 4:07 PM EDT - 2 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results

Perspective Therapeutics initiated with an Overweight at Piper Sandler

2026-02-19T10:15:14.000Z - 2 months ago

Perspective Therapeutics initiated with an Overweight at Piper Sandler

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results

Feb 17, 2026, 7:00 AM EST - 3 months ago

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results

Perspective Therapeutics prices 39.58M shares at $3.79 in underwritten offering

2026-02-02T13:46:01.000Z - 3 months ago

Perspective Therapeutics prices 39.58M shares at $3.79 in underwritten offering

Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Feb 2, 2026, 8:35 AM EST - 3 months ago

Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Perspective Therapeutics price target raised to $12 from $10 at H.C. Wainwright

2026-01-30T11:10:55.000Z - 3 months ago

Perspective Therapeutics price target raised to $12 from $10 at H.C. Wainwright

Perspective Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 5:15 PM EST - 4 months ago

Perspective Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Perspective Therapeutics provides business updates, strategic priorities

2026-01-12T12:40:27.000Z - 4 months ago

Perspective Therapeutics provides business updates, strategic priorities

Perspective presents interim results from Phase 1/2 trial of 212PbVMT-a-NET

2026-01-09T12:10:58.000Z - 4 months ago

Perspective presents interim results from Phase 1/2 trial of 212PbVMT-a-NET

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium

Jan 9, 2026, 7:00 AM EST - 4 months ago

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium

Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 7:00 AM EST - 5 months ago

Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Perspective Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 1:00 PM EST - 5 months ago

Perspective Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Perspective Therapeutics assumed with a Buy at Truist

2025-11-24T14:00:51.000Z - 6 months ago

Perspective Therapeutics assumed with a Buy at Truist

Perspective Therapeutics price target lowered to $7 from $18 at UBS

2025-11-21T12:06:25.000Z - 6 months ago

Perspective Therapeutics price target lowered to $7 from $18 at UBS

Perspective Therapeutics price target lowered to $7 from $18 at UBS

2025-11-21T00:30:21.000Z - 6 months ago

Perspective Therapeutics price target lowered to $7 from $18 at UBS

Perspective Therapeutics to Participate in Upcoming December Conferences

Nov 20, 2025, 7:00 AM EST - 6 months ago

Perspective Therapeutics to Participate in Upcoming December Conferences

Perspective Therapeutics price target lowered to $11 from $12 at B. Riley

2025-11-18T14:39:32.000Z - 6 months ago

Perspective Therapeutics price target lowered to $11 from $12 at B. Riley

TNGX

Perspective Therapeutics price target lowered to $13 from $14 at Oppenheimer

2025-11-11T12:55:15.000Z - 6 months ago

Perspective Therapeutics price target lowered to $13 from $14 at Oppenheimer

SNY

Perspective Therapeutics reports Q3 EPS (35c), consensus (32c)

2025-11-10T21:31:38.000Z - 6 months ago

Perspective Therapeutics reports Q3 EPS (35c), consensus (32c)

Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results

Nov 10, 2025, 4:05 PM EST - 6 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results

Perspective Therapeutics to Participate in Upcoming November Conferences

Oct 31, 2025, 7:00 AM EDT - 6 months ago

Perspective Therapeutics to Participate in Upcoming November Conferences

Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results

Oct 24, 2025, 7:00 AM EDT - 7 months ago

Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results

Perspective Therapeutics falls after update on Phase 1/2a trial

2025-10-20T18:10:11.000Z - 7 months ago

Perspective Therapeutics falls after update on Phase 1/2a trial

Perspective Therapeutics Transcript: Study Update

Oct 20, 2025, 8:30 AM EDT - 7 months ago

Perspective Therapeutics Transcript: Study Update

Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025

Oct 20, 2025, 4:00 AM EDT - 7 months ago

Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025

Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

Sep 3, 2025, 7:00 AM EDT - 9 months ago

Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

Perspective Therapeutics to Participate in Upcoming September Conferences

Aug 26, 2025, 7:00 AM EDT - 9 months ago

Perspective Therapeutics to Participate in Upcoming September Conferences

Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results

Aug 13, 2025, 6:45 AM EDT - 9 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025

Jul 24, 2025, 12:45 PM EDT - 10 months ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results

Jul 15, 2025, 7:00 AM EDT - 10 months ago

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results

Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial

Jun 21, 2025, 8:00 AM EDT - 11 months ago

Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting

Jun 21, 2025, 8:00 AM EDT - 11 months ago

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

May 30, 2025, 5:21 PM EDT - 1 year ago

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results

May 12, 2025, 4:36 PM EDT - 1 year ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results

Perspective Therapeutics to Participate in Upcoming May Investor Conferences

May 1, 2025, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate in Upcoming May Investor Conferences

Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting

Apr 23, 2025, 12:25 PM EDT - 1 year ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting

Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results

Apr 17, 2025, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Apr 11, 2025, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Perspective Therapeutics to Participate in Upcoming April Investor Conferences

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate in Upcoming April Investor Conferences

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results

Mar 26, 2025, 4:10 PM EDT - 1 year ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Mar 17, 2025, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Perspective Therapeutics Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 11, 2025, 3:30 PM EDT - 1 year ago

Perspective Therapeutics Transcript: Barclays 27th Annual Global Healthcare Conference

Perspective Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 11:10 AM EST - 1 year ago

Perspective Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Perspective Therapeutics to Present at Upcoming March Investor Conferences

Feb 26, 2025, 7:00 AM EST - 1 year ago

Perspective Therapeutics to Present at Upcoming March Investor Conferences

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results

Feb 21, 2025, 7:00 AM EST - 1 year ago

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results

Perspective Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 12, 2025, 2:00 PM EST - 1 year ago

Perspective Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Perspective Therapeutics to Participate in Upcoming February Investor Conferences

Feb 5, 2025, 7:00 AM EST - 1 year ago

Perspective Therapeutics to Participate in Upcoming February Investor Conferences

Perspective Therapeutics Transcript: Status Update

Jan 24, 2025, 8:00 AM EST - 1 year ago

Perspective Therapeutics Transcript: Status Update

Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

Jan 24, 2025, 7:00 AM EST - 1 year ago

Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

Perspective Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 6:45 PM EST - 1 year ago

Perspective Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer

Jan 6, 2025, 8:00 AM EST - 1 year ago

Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer

Perspective Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Dec 5, 2024, 10:50 AM EST - 1 year ago

Perspective Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Perspective Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 10:00 AM EST - 1 year ago

Perspective Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Perspective Therapeutics to Participate in Upcoming Investor Conferences in December

Nov 27, 2024, 7:00 AM EST - 1 year ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in December

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

Nov 21, 2024, 7:15 AM EST - 1 year ago

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

Perspective Therapeutics Transcript: Stifel 2024 Healthcare Conference

Nov 18, 2024, 9:10 AM EST - 1 year ago

Perspective Therapeutics Transcript: Stifel 2024 Healthcare Conference

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

Nov 15, 2024, 4:08 PM EST - 1 year ago

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

Perspective Therapeutics Transcript: UBS Global Healthcare Conference

Nov 13, 2024, 5:45 PM EST - 1 year ago

Perspective Therapeutics Transcript: UBS Global Healthcare Conference

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

Nov 12, 2024, 4:05 PM EST - 1 year ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

Oct 29, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine

Oct 23, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine

Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

Oct 16, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research

Oct 11, 2024, 8:30 AM EDT - 1 year ago

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research

Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research

Oct 10, 2024, 5:14 PM EDT - 1 year ago

Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research

Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day

Oct 7, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day

Perspective Therapeutics Inc (CATX) Trading 3.4% Higher on Oct 2

Oct 2, 2024, 12:10 PM EDT - 1 year ago

Perspective Therapeutics Inc (CATX) Trading 3.4% Higher on Oct 2

Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine

Perspective Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 17, 2024, 10:55 AM EDT - 1 year ago

Perspective Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Perspective Therapeutics Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 6, 2024, 9:15 AM EDT - 1 year ago

Perspective Therapeutics Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma

Sep 5, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma

Perspective Therapeutics to Participate in Upcoming Investor Conferences in September

Aug 28, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in September

Xanderzzzzzzz
Xanderzzzzzzz May. 13 at 3:33 PM
$CATX
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz May. 13 at 2:16 PM
$CATX
0 · Reply
jto2
jto2 May. 13 at 12:48 AM
FDA predictability is back on the menu. Bullish for $CATX.
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz May. 12 at 10:28 PM
$CADL $IOVA $CATX
5 · Reply
rughead64
rughead64 May. 12 at 5:04 PM
$CATX Morgan stanley 3 million shares
2 · Reply
watchaddict
watchaddict May. 12 at 5:03 PM
$CATX 500
0 · Reply
watchaddict
watchaddict May. 12 at 1:25 PM
$CATX 100
1 · Reply
PismoSpike
PismoSpike May. 12 at 12:06 PM
$CATX Hi folks, still seeing old timers, that's nice. How are we feeling about the stock? How's the business plan and business doing now in you and since merger? Any opinions about building a position again?
3 · Reply
rughead64
rughead64 May. 12 at 10:21 AM
$CATX short interest dropped a little, but is still 13 million.
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz May. 11 at 9:11 PM
$CATX
0 · Reply
outlawinvestor1
outlawinvestor1 May. 11 at 8:58 PM
$CATX $SNY alphamedix tox issues were documented at a radioactivity cap of 5.5 mCi. perspective has now cleared this threshold, treating 20 patients in cohort 3 at 6.0 mCi with zero cases of dysphagia reported as of the march 4, 2026, data cut. this was presented at aacr (in 16 pts). now, they've opened Cohort 4 specifically to test that "front-loaded" dosing strategy! https://perspectivetherapeutics.com/newsroom/press-release?i=165655
0 · Reply
ltcman
ltcman May. 11 at 6:23 PM
$CATX wish we were moving like LNTH!!!
0 · Reply
watchaddict
watchaddict May. 11 at 4:59 PM
$CATX 471 lfg
0 · Reply
watchaddict
watchaddict May. 11 at 3:29 PM
$CATX 700 lfg
0 · Reply
watchaddict
watchaddict May. 11 at 2:43 PM
$CATX 100 more lfg
0 · Reply
Kingtan
Kingtan May. 11 at 2:28 PM
$CATX LFG
0 · Reply
watchaddict
watchaddict May. 11 at 2:12 PM
$CATX adding
0 · Reply
RadioIsotope25
RadioIsotope25 May. 10 at 6:57 PM
$RADX $NVS $CATX $LNTH Huge Radiopharmaceutical Conference
3 · Reply
Xanderzzzzzzz
Xanderzzzzzzz May. 8 at 9:53 PM
$CATX .
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz May. 8 at 9:53 PM
$CATX Expanding the addressable market
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz May. 8 at 9:52 PM
$CATX Optimizing the entire system
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz May. 8 at 9:51 PM
$CATX First Quarter 2026 Financial Results - Press Release Only The press release will be available on the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-releases. Date: May 11, 2026 Time: After the market closes BofA Securities Health Care Conference - Fireside Chat Date: May 13, 2026 Time: 2:20 p.m. PT / 5:20 p.m. ET 2026 RBC Capital Markets Global Healthcare Conference - Fireside Chat Date: May 19, 2026 Time: 2:05 p.m. ET
1 · Reply